- Antigen tests for diagnosing COVID-19 can produce results in 15 minutes
- The FDA said that antigen tests are more affordable to produce
- There are high chances of false negatives from antigen tests: FDA
Washington: The United States Food and Drug Administration (FDA) has authorized the use of antigen test for the first time to detect and treat COVID-19 infection. “The U.S. Food and Drug Administration has issued the first emergency use authorization (EUA) for a COVID-19 antigen test, a new category of tests for use in the ongoing pandemic,” the FDA said in a statement issued on Saturday. The new type of test manufactured by Quidel Corp. It was given emergency authorization by the U.S. Food and Drug Administration on Friday night, Sputnik reported. The agency added,
One of the main advantages of an antigen test is the speed of the test, which can provide results in minutes.
Also Read: Kolkata Firm Develops Coronavirus Test Kit Costing Rs. 500
Quidel Corp. said that its test, called the Sofia 2 SARS Antigen FIA, can produce results within 15 minutes.
The FDA said that antigen tests are cheaper to produce, simpler to conduct and easier to implement at scale than the current testing apparatus. It is conducted by a nasal swab and immediately tested in the doctor’s office or other point-of-care location, producing diagnostic results within minutes by quickly detecting proteins found on or within the virus.
At the same time, antigen tests are not as sensitive to the virus as molecular PCR (Polymerase Chain Reaction) tests. The FDA said,
This means that positive results from antigen tests are highly accurate, but there is a higher chance of false negatives, so negative results do not rule out infection. With this in mind, negative results from an antigen test may need to be confirmed with a PCR test prior to making treatment decisions or to prevent the possible spread of the virus due to a false negative.
According to Johns Hopkins University, the United States has over 1.3 million confirmed cases, with the death toll at 78,320.
Also Read: Combating COVID-19: NIV-Pune Develops India’s First Antibody Testing Kit ‘ELISA’